Not applicableLooking for participantsNCT07245394
What this trial is testing
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
Who this might be right for
Inflammatory Bowel Disease (IBD)Crohn Disease (CD)Ulcerative Colitis (UC)+1 more
TIDHI Innovation Inc. 200